Type 1 Diabetes (T1D) Program - Sana's hypoimmune platform (HIP) overcomes allogeneic rejection in people, which is confirmed by 4-week and 12-week data[4] - Type 1 diabetes affects 94 million children and adults, and is projected to affect 164 million by 2040[12, 13] - Type 1 diabetes leads to 201600 deaths per year and costs $81 billion worldwide annually[17] - SC451, a HIP-modified stem cell-derived pancreatic islet therapy, is advancing toward the clinic with an expected IND filing as early as 2026[114] - HIP-modified PSC differentiated islet cells transplanted into muscle persist & control blood glucose in mice for >15 months[64] Autoimmune Disease Program - B-cell mediated autoimmune diseases affect >5 million patients[68] - SC291, a HIP-modified CD19 CAR T, leads to deep B-cell depletion and has significant potential in B-cell mediated autoimmune diseases, with an ongoing GLEAM study[114] - Sana's T cell manufacturing process provides ~85% full knock-out of MHC class I and II, >995% TCR negative cells[79] - Fusogen platform offers the potential to treat B-cell mediated autoimmune diseases and B-cell cancers with NO lymphodepletion with an expected IND filing as early as 2026[114] Oncology Program - SC262, a HIP-modified CD22 CAR T, has meaningful potential in treating CD19 CAR T relapsed patients, with an ongoing VIVID study[114] - Estimated ~12000 B cell malignancy patients treated with CD19 CAR T in 2027, with ~35-40% durable complete responses, leading to ~7500 CAR T failures annually[106]

Forward Looking Statements Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines Nasdaq: MGX May 2025 This presentation includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward looking statements, including statements regarding our cash runway, strategy and plans, industry environment, ...

For purposes of this notice, the "presentation" that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. ("Immunome") or any person on its behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. References to "we," "our," and "us" refers to Immunome and its subsidiaries. This presentation shall not cons ...

Legend Biotech CORPORATE PRESENTATION JULY 2025 The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established, except to the extent specifically provided by marketing authorizations previously received from relevant health authorities. Further, for investigational agents and/or uses, the Company cannot guarantee health authority approval or that such agents and/or uses will become commercially available in any country. Certain information cont ...

Core Viewpoint - Nektar Therapeutics experienced a decline in stock price following the completion of a secondary stock issue, resulting in a 3% loss, while the S&P 500 index rose by 0.8% [1] Group 1: Capital Raise Details - Nektar completed a secondary share flotation, selling slightly more than 4.89 million shares of common stock, including 638,298 shares sold to underwriters [2] - The gross proceeds from the share issue were approximately $115 million, priced at $23.50 per share, intended for general corporate purposes, including drug development and research activities [4] Group 2: Impact on Shareholders - The secondary share flotation is dilutive to existing shareholders, increasing the total share count from slightly more than 12.4 million to nearly 17.4 million shares, which negatively impacts shareholder value [5] - Investors are concerned about potential future equity offerings, which could lead to further dilution of shares [7] Group 3: Company Pipeline and Potential - Nektar has several pipeline projects in development, with its leading candidate, rezpegaldesleukin, showing promising results for treating moderate-to-severe atopic dermatitis [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that due to these misrepresentations, PepGen was likely to halt the CONNECT2 study, leading to overstated clinical, regulatory, and commercial prospects for PGN-ED051 [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result of the misleading statements [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong reputation in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Iovance provided misleadingly positive statements while concealing material adverse facts about its growth potential and ability to meet demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

Shares of Nurix Therapeutics, Inc. (NRIX) have gained 2.3% over the past four weeks to close the last trading session at $12.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30.28 indicates a potential upside of 143.4%.The average comprises 18 short-term price targets ranging from a low of $16.00 to a high of $41.00, with a standard deviation of $6.49. While the lowest estim ...

Corporate Strategy & Financial Position - BioNTech plans to strengthen its position through the acquisition of Biotheus, securing global control of BNT327 and expanding its immunotherapy capabilities[8] - The company reported a strong balance sheet with approximately €174 billion in total cash, cash equivalents, and security investments as of December 31, 2024[8] Oncology Pipeline & Clinical Development - BioNTech is advancing its oncology portfolio with 15 ongoing Phase 2 and Phase 3 trials[8] - BNT327 is being studied in 20+ clinical trials across multiple indications, with 3 global potentially registrational trials planned[36] - BNT327, in combination with chemotherapy, demonstrated a 738% objective response rate (ORR) in the ITT population in 1L TNBC[40] - Autogene cevumeran induced neoantigen-specific T cell responses in 71% of patients in a first-in-human study[65] mRNA Cancer Immunotherapy & Technology - BioNTech is prioritizing novel mRNA cancer immunotherapy, including FixVac and iNeST, targeting tumor-associated antigens and mutations[24] - The company has treated >450 patients and selected 18000 neoantigens using its iNeST platform[15] - BioNTech is leveraging AI to enhance its scientific capabilities and pioneer personalized immunotherapies[12] 2025 Priorities & Outlook - In 2025, BioNTech expects multiple randomized Phase 2 data readouts and will execute 7 ongoing Phase 2 trials and first novel combination trials[91] - The company aims to advance 3 global registration-enabling trials in potential fast-to-market indications in 2025[92]